Effectiveness of MeroGel hyaluronic acid on tympanic membrane perforations

Ozturk K., Yaman H., Avunduk M. C., Arbag H., Keles B., UYAR Y.

Acta Oto-Laryngologica, cilt.126, sa.11, ss.1158-1163, 2006 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 126 Sayı: 11
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1080/00016480600678797
  • Dergi Adı: Acta Oto-Laryngologica
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1158-1163
  • Anahtar Kelimeler: application, esterified hyaluronic acid, healing, perforation, tympanic membrane
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Conclusions. Our results support the proposition that hyaluronic acid (HA) provides a moist wound-healing environment to aid in the healing process of tympanic membrane perforation. A single MeroGel administration can be effective as well as daily topical HA application in the treatment of tympanic membrane perforations. A single application of esterified HA may be more suitable for patients and also for otolaryngologists. Objective . The purpose of the present study was to evaluate the effectiveness of a single MeroGel application on traumatic tympanic membrane perforations in rats. Materials and methods. The posterior quadrant of the tympanic membranes in both ears of 24 male pathogen-free Sprague-Dawley rats was perforated with a 20-gauge needle. Subjects were divided into two groups: MeroGel and daily topical HA-treated groups. All subjects were sacrificed and histopathological examinations of the tympanic bullas were carried out. Results. Perforations of controls, and MeroGel- and daily HA-treated groups closed in 17/24 (70.8%), 11/12 (91.7%), and 12/12 (100%) ears, respectively. There was a significant difference between control and MeroGel-treated groups, and also between control and daily topical HA-treated groups for the presence of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), lymphocytes and collagen fibrils (p <0.05), whereas there was no significant difference between MeroGel- and daily topical HA-treated groups (p >0.05). © 2006 Taylor & Francis.